selpertinib作为ret改变的甲状腺乳头状癌的新辅助治疗：2例报告。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE Oral oncology Pub Date : 2025-02-01 DOI:10.1016/j.oraloncology.2024.107140

Shi-Tong Yu , Da Huang , Chengfeng Xiong , Rong Xie , Jichun Yu

{"title":"selpertinib作为ret改变的甲状腺乳头状癌的新辅助治疗：2例报告。","authors":"Shi-Tong Yu , Da Huang , Chengfeng Xiong , Rong Xie , Jichun Yu","doi":"10.1016/j.oraloncology.2024.107140","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Locally advanced papillary thyroid carcinoma (PTC) with <em>RET</em> fusion–positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a <em>RET</em> kinase inhibitor, has been approved for the treatment of advanced or metastatic <em>RET</em>-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced <em>RET</em>-altered thyroid cancer is unclear.</div><div><em>Case Presentation:</em> We report two cases of <em>RET</em> fusion–positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.</div></div><div><h3>Conclusion</h3><div>Selperctinib isa potential neoadjuvant treatment for PTC with <em>RET</em> fusion–positive.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"161 ","pages":"Article 107140"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports\",\"authors\":\"Shi-Tong Yu , Da Huang , Chengfeng Xiong , Rong Xie , Jichun Yu\",\"doi\":\"10.1016/j.oraloncology.2024.107140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Locally advanced papillary thyroid carcinoma (PTC) with <em>RET</em> fusion–positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a <em>RET</em> kinase inhibitor, has been approved for the treatment of advanced or metastatic <em>RET</em>-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced <em>RET</em>-altered thyroid cancer is unclear.</div><div><em>Case Presentation:</em> We report two cases of <em>RET</em> fusion–positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.</div></div><div><h3>Conclusion</h3><div>Selperctinib isa potential neoadjuvant treatment for PTC with <em>RET</em> fusion–positive.</div></div>\",\"PeriodicalId\":19716,\"journal\":{\"name\":\"Oral oncology\",\"volume\":\"161 \",\"pages\":\"Article 107140\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1368837524004585\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837524004585","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

摘要

背景：RET融合阳性的局部晚期甲状腺乳头状癌（PTC）由于肿瘤侵入关键结构，对手术切除提出了重大挑战。新辅助靶向治疗是一种很有前途的方法，可以减轻肿瘤负担，提高可切除性。Selperctinib是一种RET激酶抑制剂，已被批准用于治疗晚期或转移性RET改变的甲状腺癌。然而，selpertinib作为局部晚期ret改变甲状腺癌新辅助治疗的疗效尚不清楚。病例介绍：我们报告了两例RET融合阳性的PTC，接受selperctinib （160 mg，每日2次）的新辅助治疗，以减小肿瘤大小并使根治性切除成为可能。用selpertinib进行新辅助治疗后，肿瘤大小减小。患者成功完成R0切除术，无重大手术并发症。结论：selpertinib是治疗RET融合阳性PTC的新辅助治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports

Background

Locally advanced papillary thyroid carcinoma (PTC) with RET fusion–positive poses significant challenges for surgical resection due to tumor invasion into critical structures. Neoadjuvant targeted therapies are a promising approach to reduce the tumor burden and improve the resectability. Selperctinib, a RET kinase inhibitor, has been approved for the treatment of advanced or metastatic RET-altered thyroid cancer. However, the efficacy of selperctinib as a neoadjuvant treatment for locally advanced RET-altered thyroid cancer is unclear.

Case Presentation: We report two cases of RET fusion–positive PTC that received neoadjuvant treatment with selperctinib (160 mg twice daily) to reduce the tumor size and enable for radical resection. Tumor sizes were reduced after neoadjuvant treatment with selperctinib. Patients successfully underwent R0 resection with no major surgical complications.

Conclusion

Selperctinib isa potential neoadjuvant treatment for PTC with RET fusion–positive.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oral oncology 医学-牙科与口腔外科

CiteScore

8.70

自引率

10.40%

发文量

505

审稿时长

20 days

期刊介绍： Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck. Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.